03
Mar

Rare disease magnate Alexion is aligning itself with biotech Blueprint Medicines, borrowing the company’s development technology to spotlight new treatments for genetic disorders.

…read more

Source: Alexion bets up to $265M on Blueprint’s precision medicine platform

    

0 No comments